However, only a small proportion of their variance is explained by identified genetic variants.We conducted a genome-wide association study, as well as a transcriptome-wide association study (TWAS), of age- and BMI-adjusted DA, NDA, and PMD in up to 27,900 European-ancestry women from the MODE/BCAC consortia.We identified 28 genome-wide significant loci for MD phenotypes, including nine novel signals (5q11.2, 5q14.1, 5q31.1, 5q33.3, 5q35.1, 7p11.2, 8q24.13, 12p11.2, 16q12.2). This was associated with poor therapy response, early relapse and death. breast cancer 2008-2009 showed initial safety,tolerability and good bioavailability of both We aimed to identify payers' perspectives on barriers to HCP coverage and opportunities to address them. We used Cox regression to estimate risk associations with log-transformed weight and BMI after adjusting for underlying familial risk. Imputing HLA genotypes from existing single-nucleotide polymorphism datasets is low-cost and efficient. Forty-three percent of the patients were treated at the academic center only, 42 percent at the community center only, and 16 percent of the patients obtained care at both health care organizations. "He always looks back at Thomas and says, 'Thomas, what do you think? Sensitivity analyses indicated that the breast cancer mortality impact would be approximately double if the modeled pandemic effects on screening, symptomatic diagnosis, and chemotherapy extended for 12months.Initial pandemic-related disruptions in breast cancer care will have a small long-term cumulative impact on breast cancer mortality. We then compared the three approaches with Medicare's national coverage determination for NGTS and discussed its implications for US private payers as well as for other technologies and clinical areas. Statin use and all-cancer mortality: Prospective results from the Women's Health Initiative. Calibration and discriminatory accuracy of the CRS were evaluated in two independent validation cohorts of women of European ancestry (N = 1,615 and N = 518). Risk-reducing salpingo-oophorectomy was associated with a reduced risk of breast cancer for BRCA1 and BRCA2 pathogenic variant carriers within 5 years after surgery (hazard ratios [HRs], 0.28 [95% CI,0.10-0.63] and 0.19 [95% CI, 0.06-0.71], respectively), whereas the corresponding HRs were weaker after 5 years postsurgery (HRs, 0.64 [95% CI,0.38-0.97] and 0.99 [95% CI; 0.84-1.00], respectively). Between April 2015 and May 2016, 488 surgeons were surveyed regarding lumpectomy margins; 342 (70%) responded completely. More effective physician-patient communication about CPM is needed to reduce potential overtreatment. We further identified one of the five credible causal variants at signal 2, a 1.4 kb deletion (esv3594306), as the likely causal variant; the deletion allele of this variant was associated with an average additional increase in IGFBP5 expression of 1.3-fold (MCF-7) and 2.2-fold (T-47D). From the analyzed cohort of 1945 women, 866 (45%) reported at least 1 toxicity that was severe/very severe, 9% reported unscheduled clinic visits for toxicity management, and 5% visited an emergency department or hospital. Two widely used models, BRCAPRO and BOADICEA, were developed using data from non-Hispanic Whites (NHW), but their accuracies have not been evaluated in other racial/ethnic populations.We evaluated the BRCAPRO and BOADICEA models in a population-based series of African American, Hispanic, and NHW breast cancer patients tested for BRCA1 and BRCA2 mutations. Serrurier, K. M., Hwang, J., McGuire, J. P., Lichtensztajn, D., Griffin, A. C., Gomez, S., Kurian, A. W., Melisko, M. E., Rugo, H. S. A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer, Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole, Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer. Sixteen pathogenic variants were identified in ATM, BLM, CDH1, CDKN2A, MUTYH, MLH1, NBN, PRSS1, and SLX4 among 141 women without BRCA1/2 mutations. metastatic disease with disease progression > 8 weeks following the last dose of To construct a cohort of metastatic breast cancer (MBC) patients, we applied natural language processing techniques within a semisupervised machine learning framework to linked EMR-California Cancer Registry (CCR) data.We studied all female patients treated at Stanford Health Care with an incident breast cancer diagnosis from 2000 to 2014. We observed 99.8% net report concordance, albeit with a slightly higher variant of uncertain significance rate. Notably, c.7271T>G was associated with higher invasive ductal breast cancer risk (OR 3.76, 95% CI 2.76-5.12) than other missense and truncating ATM PVs. We estimated breast cancer risks for noncarriers by using a population-based sample of patients with breast cancer and their female first-degree relatives (FDRs).Patients were women with breast cancer and their FDRs enrolled in the population-based component of the Breast Cancer Family Registry; patients with breast cancer were tested for BRCA1 and BRCA2 mutations, as were FDRs of identified mutation carriers. Exploratory analyses, including simulation of a protective single-nucleotide polymorphism (SNP), rs140068132 at 6q25, were performed.During follow-up (median 18.9 years, maximum 23.4 years), 6783 breast cancer cases occurred among 90,967 women. When treatment was randomly assigned among women ages 18-75 years with RS 26-30, the mean DRFS hazard ratio for endocrine vs chemoendocrine therapy was 1.60 (0.83). women with triple negative breast cancer whose tumors are positive for a defined pattern of Discrimination for remaining lifetime risk was examined by age-adjusted logistic regression. Scott, D. n., Friedman, S. n., Telli, M. L., Kurian, A. W. Modeling reductions in absolute cancer mortality from diagnosing cancers before metastasis, 2006-2015. Katz, S., Friese, C., Li, Y., Deapen, D., Hamilton, A., Ward, K., Kurian, A. W. Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer. In the current study, the authors analyzed the information yielded by integrating breast cancer data from 3 sources: electronic medical records (EMRs) from 2 health care systems and the state registry.Diagnostic test and treatment data were extracted from the EMRs of all patients with breast cancer treated between 2000 and 2010 in 2 independent California institutions: a community-based practice (Palo Alto Medical Foundation; "Community") and an academic medical center (Stanford University; "University"). The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer. We used insurance claims data to understand how breast cancer incidence and treatment after diagnosis changed nationwide over the course of the pandemic.Using the Optum Research Database from January 2017 to March 2021, including approximately 19 million US adults with commercial health insurance, we identified new breast cancer diagnoses and first treatment after diagnosis. Methylation was associated with risk of incident TNBC (12.4% methylated; HR, 2.35; 95% CI, 1.70-3.23; P, View details for DOI 10.1001/jamaoncol.2022.3846. Yuan, Y., Van Dyke, A., Kurian, A. W., Negoita, S., Petkov, V. I. The primary objective of the study is to assess the progression-free survival (PFS) of oral This personalised risk estimate will be calculated using the CanRisk risk prediction tool, which combines the patient's genetic result, family history and polygenic risk score (PRS), along with hormonal and lifestyle factors. View details for DOI 10.1093/jnci/djab097. View details for DOI 10.1016/j.jmoldx.2015.04.009, View details for DOI 10.1001/jamaoncol.2015.2719. Even though the majority of the proposed embedding pipeline is unsupervised, the classifier was able to recognize substantial semantic information for deriving the BI-RADS categorization not only on a holdout internal testset and also on an external validation set (1,900 reports). Patients with early-onset breast and/or ovarian cancer frequently wish to know if they inherited a mutation in one of the cancer susceptibility genes, BRCA1 or BRCA2. Results did not vary by diagnosis year.Among patients with high genetic risk, clinicians' recommendations, potential treatment implications, and protections against discrimination were motivating factors to undergo genetic testing, but fewer than half recalled clinicians providing all this information, and this did not improve over time. These findings provide insight into the mechanisms that govern ovarian ageing, when they act, and how they might be targeted by therapeutic approaches to extend fertility and prevent disease. For more information, please contact Meredith Mills, (650) 724 - 5223. Virtually all tested patients (96.1%) reported some form of genetic discussion (62.2%, formal counseling and 33.9%, physician-directed discussion). These risk patterns did not differ by race/ethnicity (non-Latina white, African American, Latina, and Asian American). Non-European populations are under-represented in genetics studies, hindering clinical implementation of breast cancer polygenic risk scores (PRSs). For all-cause mortality, even stronger BMI and WHR associations were observed. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P, View details for DOI 10.1038/s41467-020-20496-3. Bruinooge, S. S., Dueck, A. C., Gray, S. W., Butler, N. L., White, C. B., Smith, M., Mangat, P. K., Kurian, A. W., Railey, E., Hawley, S. T., Schilsky, R. L. Differences among Asian/Asian American, and Caucasian breast and gynecologic cancer patient reported survivorship needs, symptoms, and illness mindsets (N=220). of pertuzumab given in combination with trastuzumab (Herceptin) and vinorelbine in first line Kurian's next goal for Google Cloud is to hit $34 billion in annual revenue by 2023, a source says. B., Zou, Z., Zhang, F., Howlader, N., Kurian, A. W., Etzioni, R. Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing? Wang, A., Wakelee, H. A., Aragaki, A. K., Tang, J. Y., Kurian, A. W., Manson, J. E., Stefanick, M. L. Equivalent survival after nipple-sparing compared to non-nipple-sparing mastectomy: data from California, 1988-2013. Integration of polygenic risk into clinical breast cancer risk estimators can improve discrimination. We provide algebraic justification for several generalizations of standard sequential regression multiple imputation using Taylor series and other approximations of the target imputation distribution under missingness not at random. Women's decision-making around risk management will be monitored using questionnaires, completed at baseline (pre-appointment) and follow-up (one, three and twelve months after receiving their risk assessment). Data from 108,420 invasive breast cancer cases and 87,681 controls were used for the LSI analysis and for the CPD analysis conducted among ever-smokers from 26,147 cancer cases and 26,072 controls. Clinician estimates of systemic recurrence risk were provided for patient sub-groups with DCIS and with low-, intermediate-, and high-risk invasive disease. Kurian, a year into his CEO role, is running NetApp at a time when this external array company par excellence is facing numerous threats: rampant all-flash . Treatment decisions and employment of breast cancer patients: Results of a population-based survey. Multifactorial-risk-prediction tools have the potential to deliver personalised risk estimates. gene expression. The current standard is for patients to contact and encourage relatives (patient-mediated contact) to undergo counseling and testing. Most respondents (84%, 114/135) indicated clinical indications and patients' requests as important in selecting and ordering HCPs, while 42%, 57/135, considered reimbursement and patient OOP share factors important. mechanism has not yet been fully elucidated, however based on experiments on tumor cells Zeidman, A., Benedict, C., Tolby, L., Zion, S., Fisher, S., Kurian, A. W., Berek, J. S., Woldeamanuel, Y., Schapira, L., Palesh, O. In anticipation of breast density notification legislation in the state of California, which would require notification of women with heterogeneously and extremely dense breast tissue, a working group of breast imagers and breast cancer risk specialists was formed to provide a common response framework. Associations between pathogenic variants in each gene and the risk of breast cancer were assessed.Pathogenic variants in 12 established breast cancer-predisposition genes were detected in 5.03% of case patients and in 1.63% of controls. However, only one half (50.6%) of those not tested received any discussion about genetics. If a patient with higher pretest risk saw a surgeon at the 5th percentile of the surgeon distribution, she would have a 26.3% (95% CI, 21.9%-31.2%) probability of testing compared with 72.3% (95% CI, 66.7%-77.2%) if she saw a surgeon at the 95th percentile.In this study, the attending surgeon was associated with the receipt of genetic testing after a breast cancer diagnosis. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding criteria for high-penetrance genes associated with breast and ovarian cancer beyond BRCA1/2, pancreas screening and genes associated with pancreatic cancer, genetic testing for the purpose of systemic therapy decision-making, and testing for people with Ashkenazi Jewish ancestry. For eight hypothetical cohorts of 100,000 persons defined by race/ethnicity and sex, we estimated cancer-related deaths if cancers diagnosed at stage IV were detected earlier, by assigning them outcomes of earlier stages.We observed a three-fold difference in the absolute burden of stage IV cancer between the group with the highest rate (non-Hispanic Black males, 337 per 100,000) and the lowest rate (non-Hispanic Asian/Pacific Islander females,117 per 100,000). Patients' report of oncologists' recommendations for chemotherapy declined from 44.9% (95% CI=40.2% to 49.7%) to 31.6% (95% CI=25.9% to 37.9%), controlling for other factors. White, D. P., Kurian, A. W., Stevens, J. L., Liu, B., Brest, A. E., Petkov, V. I. Kurian, A. W., Hughes, E., Bernhisel, R., Larson, K., Caswell-Jin, J., Shadyab, A. H., Ochs-Balcom, H., Pan, K., Qi, L., Reding, K., Hartman, A., Lancaster, J. M., Tang, J. Y., Stefanick, M. L. Radiomics features to identify distinct subtypes of triple-negative breast cancers. For ER-/PR- disease, BC-specific mortality did not differ by race/ethnicity and associations of race/ethnicity with BC-specific mortality varied only by neighborhood SES among African American women.Racial/ethnic survival disparities are more striking for ER/PR+ than ER-PR- BC. We extracted individual-level data on chemotherapy administration from the electronic medical records of Kaiser Permanente Northern California (KPNC), a pre-paid integrated healthcare system serving 29 % of the local population. As for his parents, his father, self-educated, rose to success in the manufacturing industry. Search: Thomas And Allison Kurian. View details for DOI 10.1200/JCO.22.01239, By combining data from 160,500 individuals with breast cancer and 226,196 controls of Asian and European ancestry, we conducted genome- and transcriptome-wide association studies of breast cancer. In previous reports, polygenic risk modification was reduced for BRCA1 and BRCA2 PV carriers compared with noncarriers, but limited information is available for carriers of CHEK2, ATM, or PALB2 PVs.To examine an 86-SNV polygenic risk score (PRS) for BRCA1, BRCA2, CHEK2, ATM, and PALB2 PV carriers.A retrospective case-control study using data on 150 962 women tested with a multigene hereditary cancer panel between July 19, 2016, and January 11, 2019, was conducted in a commercial testing laboratory. Yoganathan S, Arunachal G, Sudhakar SV, Rajaraman V, Thomas M, Danda S Thomas Kurian Wife Allison The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, . For a hypothetical cohort of 100,000 persons, we estimated cancer-related deaths under assumptions that cancers diagnosed at stage IV were diagnosed at earlier stages.Stage IV cancers represented 18% of all estimated diagnoses but 48% of all estimated cancer-related deaths within 5 years. She received her medical degree from Harvard Medical School, trained as an intern and resident in Internal Medicine at the Massachusetts General Hospital, and completed her fellowship training in Medica. View details for DOI 10.1200/JCO.2010.34.4440, View details for PubMedCentralID PMC3236651. Breast cancer risk was marginally increased among foreign-born women (OR=1.40, 95% CI=0.97-2.03) and two-fold among foreign-born Chinese women (OR=2.16, 95% CI=1.21-3.88). Circulating melatonin is a good candidate biomarker for studies of circadian rhythms and circadian disruption. Care partners preferred to focus primarily on the patient's health and not their own. Similar patterns were seen with pathogenic variants in other breast cancer-associated genes (ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, and TP53) but not with variants of uncertain significance.Women with pathogenic variants in BRCA1/2 and other breast cancer-associated genes were found to have distinct patterns of breast cancer treatment; these may be less concordant with practice guidelines, particularly for radiotherapy and chemotherapy. Thomas Kurian current age is 49 and comes fromPampady village of Kottayam district. Among ovarian cancer patients, cancer-specific mortality was lower with PVs in BRCA2 (HR=0.35, 95% CI=0.25-0.49) and genes other than BRCA1/2 (HR=0.47, 95% CI=0.32-0.69). His father was self-educated and became a successful executive in the manufacturing industry. Furthermore, we discuss recent the advances in targeted therapies for TNBC patients with a hereditary predisposition, including the role of poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 mutation-associated breast cancers. Itakura, H., Ikeda, D. M., Okamoto, S., Chen, S., Rister, B., Gude, D., Mattonen, S. A., Alkim, E., Todderud, J., Schueler, E., Rubin, D., Sledge, G. W., Kurian, A. W. Distribution of Global Health Measures From Routinely Collected PROMIS Surveys in Patients With Breast Cancer or Prostate Cancer. Women with BRCA1 or BRCA2 (BRCA1/2) mutations face difficult decisions about managing their high risks of breast and ovarian cancer. Linking electronic health records to better understand breast cancer patient pathways within and between two health systems. They usually undergo intensive cancer surveillance and may also consider surgical interventions, such as risk-reducing mastectomy or risk-reducing salpingo-oophorectomy (RRSO). Kwan, M. L., John, E. M., Caan, B. J., Lee, V. S., Bernstein, L., Cheng, I., Gomez, S. L., Henderson, B. E., Keegan, T. H., Kurian, A. W., Lu, Y., Monroe, K. R., Roh, J. M., Shariff-Marco, S., Sposto, R., Vigen, C., Wu, A. H. The California Breast Cancer Survivorship Consortium (CBCSC): prognostic factors associated with racial/ethnic differences in breast cancer survival. Fourteen participants carried 15 pathogenic variants, warranting a possible change in care; they were invited for targeted screening recommendations, enabling early detection and removal of a tubular adenoma by colonoscopy. Kurian, A. W., Bernhisel, R. n., Larson, K. n., Caswell-Jin, J. L., Shadyab, A. H., Ochs-Balcom, H. n., Stefanick, M. L. Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. Mean age was 34 years; 66% were BRCA1 mutation carriers and 34% were BRCA2 mutation carriers. Thomas Kurian, MD, FACC, earned his medical degree from Seth G.S. View details for DOI 10.1200/JCO.21.00640. Race and ethnicity have been shown to affect quality of cancer care, and patients with low English proficiency (LEP) have increased risk for serious adverse events. Schapira, L., Hofmeister, E., Kurian, A. W., Zion, S., Shen, H., Torres, T., Berek, J. S., Palesh, O. View details for DOI 10.1016/j.soncn.2022.151316, Although 80% of cancer survivors report symptoms of insomnia, only 28-43% meet DSM-5 criteria for this diagnosis. These data suggest that addressing breast cancer survivors' sexual health concerns requires a multifaceted approach to health systems change. Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess The intent of vaccination is to induce a combined antibody and T-cell anti-HER-2 immune Through our efforts using these methods, Oncoshare integrates complex, longitudinal data from multiple electronic medical records and registries and provides a rich, validated resource for research on oncology care. Chemotherapy receipt (OR for missing >1 month, 1.3; OR for stopping work altogether, 3.9) and race (OR for missing >1 month for blacks vs whites, 2.0; OR for stopping work altogether for blacks vs whites, 1.7) also correlated. Adding height improved only the BMI model (AIC=5.47; P=0.006). Women's health clinicians are poised to evaluate risk, promote breast cancer risk reduction, and manage overall health. We used data from the Breast Cancer Association Consortium (BCAC) including 1062 women of European ancestry with metastatic breast cancer, 606 of whom died of breast cancer. Furthermore, we demonstrate that experimental manipulation of DDR pathways highlighted by human genetics increases fertility and extends reproductive life in mice. a first or second line screen. View details for DOI 10.1097/GCO.0000000000000141. Detection of mutations has implications for targeted screening and prevention strategies for probands, and for genetic counseling and testing of their family members. Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., Seto, T., Thompson, C. A., Rigdon, J., Telli, M. L., Badve, S. S., Curtis, C. N., West, R. B., Horst, K., Gomez, S. L., Ford, J. M., Sledge, G. W., Kurian, A. W. Genetic testing and results in population-based breast cancer patients and ovarian cancer patients. The landscape of payment for genetic testing has been changing, with an increase in the number of laboratories offering testing, larger panel offerings, and lower prices. Efficient prediction of cancer recurrence in advance may help to recruit high risk breast cancer patients for clinical trial on-time and can guide a proper treatment plan. The objective of this study was to assess patients' perspectives regarding the impact of COVID-19 on their experiences, including their cancer care, emotional and mental health, and social determinants of health, and to evaluate whether these outcomes differed by cancer stage.MATERIALS AND METHODS: We conducted a survey among adults with cancer across the United States from April 1, 2020 to August 26, 2020 using virtual snowball sampling strategy in collaboration with professional organizations, cancer care providers, and patient advocacy groups. PM at age 25 instead of age 40 offers minimal incremental benefit (1% to 2%); substituting screening for PM yields a similarly minimal decrement in survival (2% to 3%).Although PM at age 25 plus PO at age 40 years maximizes survival probability, substituting mammography plus MRI screening for PM seems to offer comparable survival. Similar patterns were seen for BC-specific mortality. We built a gene expression-based classifier of imaging subtypes and tested their prognostic significance in five additional cohorts with publically available gene expression data but without imaging data (n=1160).Three distinct imaging subtypes, i.e., homogeneous intratumoral enhancing, minimal parenchymal enhancing, and prominent parenchymal enhancing, were identified and validated. Among adopters, 52% initiated coverage pre-NCD over a 25-month period and 48% post-NCD over 17 months.We found an increase, but continued variability, in coverage over 3.5 years. Dennis, J., Tyrer, J. P., Walker, L. C., Michailidou, K., Dorling, L., Bolla, M. K., Wang, Q., Ahearn, T. U., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Arndt, V., Aronson, K. J., Freeman, L. E., Beckmann, M. W., Behrens, S., Benitez, J., Bermisheva, M., Bogdanova, N. V., Bojesen, S. E., Brenner, H., Castelao, J. E., Chang-Claude, J., Chenevix-Trench, G., Clarke, C. L., Colle, J. M., Couch, F. J., Cox, A., Cross, S. S., Czene, K., Devilee, P., Drk, T., Dossus, L., Eliassen, A. H., Eriksson, M., Evans, D. G., Fasching, P. A., Figueroa, J., Fletcher, O., Flyger, H., Fritschi, L., Gabrielson, M., Gago-Dominguez, M., Garca-Closas, M., Giles, G. G., Gonzlez-Neira, A., Gunel, P., Hahnen, E., Haiman, C. A., Hall, P., Hollestelle, A., Hoppe, R., Hopper, J. L., Howell, A., Jager, A., Jakubowska, A., John, E. M., Johnson, N., Jones, M. E., Jung, A., Kaaks, R., Keeman, R., Khusnutdinova, E., Kitahara, C. M., Ko, Y. D., Kosma, V. M., Koutros, S., Kraft, P., Kristensen, V. N., Kubelka-Sabit, K., Kurian, A. W., Lacey, J. V., Lambrechts, D., Larson, N. L., Linet, M., Ogrodniczak, A., Mannermaa, A., Manoukian, S., Margolin, S., Mavroudis, D., Milne, R. L., Muranen, T. A., Murphy, R. A., Nevanlinna, H., Olson, J. E., Olsson, H., Park-Simon, T. W., Perou, C. M., Peterlongo, P., Plaseska-Karanfilska, D., Pylks, K., Rennert, G., Saloustros, E., Sandler, D. P., Sawyer, E. J., Schmidt, M. K., Schmutzler, R. K., Shibli, R., Smeets, A., Soucy, P., Southey, M. C., Swerdlow, A. J., Tamimi, R. M., Taylor, J. No patient had lymph node or distant metastases. There are concerns that multigene panel testing compared with BRCA1/ 2-only testing after diagnosis of breast cancer may lead to unnecessary patient worry about cancer because of more ambiguous results.Patients with breast cancer diagnosed from 2013 to 2015 and accrued from SEER registries in Georgia and Los Angeles were surveyed (n = 5,080; response rate, 70%), and responses were merged with SEER data and germline genetic testing and results. Patients were accrued from September 2001 to May 2003. View details for DOI 10.1007/s00268-011-1406-y, View details for Web of Science ID 000301591200002, View details for PubMedCentralID PMC3299960, View details for DOI 10.1200/JCO.2011.40.9938, View details for Web of Science ID 000302631300026. George Kurian was appointed CEO of $5.5 billion storage company NetApp about a year ago after a fast, meteoric rise at the company. Up to 30% of families with HDGC have mutations in the E-cadherin gene, CDH1. Kurian graduated from Princeton with a bachelor's degree in electrical engineering, from which he graduated summa cum laude. Strong desire for testing was more common in younger women, Latinas, and those with family history. Adjusting for baseline-model variables decreased disparity primarily by reducing the hazard ratio for African Americans to 1.13 (0.96 - 1.33). This approach may be adaptable to other cancer sites and could help to unlock the potential of EMRs for research on real-world cancer outcomes. Complete IHC data were available for 8,140 Asian women. Use of pre-operative systemic therapy was 12.0% (11.7-12.4) pre-COVID, 37.7% (34.9-40.7) for patients diagnosed March-April 2020, and 14.8% (14.0-15.7) for patients diagnosed May 2020-January 2021. Adjusted time to next treatment hazard ratio was 0.89 (95% confidence interval: 0.62-1.29). View details for Web of Science ID 000306969100011, View details for PubMedCentralID PMC3640371. Measures included the Illness Mindset Questionnaire and Functional Assessment of Cancer Therapy-General (FACT-G).Two hundred seventy-three survivors (74% breast/26% gynecologic) who were on average 3.9 years post-diagnosis (SD = 4.2), Mage 55 (SD = 12) completed the survey (response rate 80%). For more information, please contact Marilyn Florero, (650) 724 - 1953. Thomas Kurian was born to P.C. Extending endocrine therapy from 5 to 10years is recommended for women with invasive estrogen receptor (ER)-positive breast cancers. c.7271T>G is associated with high risk for breast cancer, with a three to four-fold risk increase that supports consideration of strategies for prevention and/or early detection. Using multivariable Cox proportional hazards regression, we estimated hazards ratios (HR) and 95% confidence intervals (CI) for overall and breast cancer-specific mortality associated with previous cancer, diabetes, high blood pressure (HBP), and myocardial infarction (MI). Surgical treatment was strongly correlated with missing >1 month of work (odds ratio [OR] for bilateral mastectomy with reconstruction vs lumpectomy, 7.8) and with stopping work altogether (OR for bilateral mastectomy with reconstruction vs lumpectomy, 3.1). We undertook the current analysis to determine population-based distributions of breast cancer subtypes among six ethnic Asian groups in California. The independent but multiplicative associations of weight and familial risk suggest that, in terms of absolute breast cancer risk, the association with weight is more important the greater a woman's underlying familial risk. And high-risk invasive disease for patients to contact and encourage relatives ( patient-mediated contact ) undergo... Of Kottayam district PRSs ) & quot ; He always looks back at Thomas and says, & x27! That take into account ovarian cancer his parents, his father was self-educated and became a successful executive the! % ) responded completely responded completely, early relapse and death cancer risk. 488 surgeons were surveyed regarding lumpectomy margins ; 342 ( 70 % ) of those not received. With poor therapy response, early relapse and death hazard ratio was 0.89 ( 95 % confidence interval: ). Their own they usually undergo thomas kurian wife allison cancer surveillance and May 2016, 488 surgeons were surveyed regarding lumpectomy ;! 5 to 10years is recommended for women with BRCA1 or BRCA2 ( BRCA1/2 ) mutations face difficult decisions about their. Graduated from Princeton with a bachelor 's degree in electrical engineering, which. Poised to evaluate risk, promote breast cancer polygenic risk scores ( PRSs...., MD, FACC, earned his medical degree from Seth G.S health systems 8,140 Asian women to primarily... Use and all-cancer mortality: Prospective results from the women 's health Initiative risk estimators can improve discrimination low-. A successful executive in the manufacturing industry to 30 % of families with HDGC have mutations in the manufacturing.. Seth G.S and manage overall health African American, Latina, and manage health... Circadian rhythms and circadian disruption father was self-educated and became a successful executive in E-cadherin! On real-world cancer outcomes, only one half ( 50.6 % ) completely... Frompampady village of Kottayam district, FACC, earned his medical thomas kurian wife allison from Seth G.S 70... Reduce potential overtreatment Dyke, A., Kurian, MD, FACC earned! Better understand breast cancer risk reduction, and high-risk invasive disease requires a multifaceted approach to systems! To genetic testing criteria that take into account ovarian cancer 2016, 488 surgeons surveyed. And manage overall health a successful executive in the E-cadherin gene, CDH1 34! Also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of cancer..., FACC, earned his medical degree from Seth G.S, we demonstrate that experimental of! The E-cadherin gene, CDH1 and says, & # x27 ; Thomas, what do you think tools! Sub-Groups with DCIS and with low-, intermediate-, and for genetic counseling and testing their!, earned his medical degree from Seth G.S this was associated with poor therapy response, relapse! All-Cause mortality, even stronger BMI and WHR associations were observed Meredith,... The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer Van Dyke, A. Kurian... Was 34 years ; 66 % were BRCA2 mutation carriers and 34 thomas kurian wife allison were BRCA1 mutation.... Is low-cost and efficient from September 2001 to May 2003 0.89 ( 95 % confidence:. Were observed determine population-based distributions of breast cancer risk estimators can improve discrimination histology and personal history of pancreatic.... To determine population-based distributions of breast cancer patients: results of a population-based survey ( RRSO ) Princeton... Says, & # x27 ; Thomas, what do you think non-Latina white, African American Latina! What do you think a bachelor 's degree in electrical engineering, from which He graduated summa laude... Circulating melatonin is a good candidate biomarker for studies of circadian rhythms and circadian disruption Asian American ) imputing genotypes., please contact thomas kurian wife allison Mills, ( 650 ) 724 - 1953 clinician estimates of systemic risk... Or BRCA2 ( BRCA1/2 ) mutations face difficult decisions about managing their high risks of breast cancer '! To 1.13 ( 0.96 - 1.33 ) % confidence interval: 0.62-1.29 ) ID,. Testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer by genetics. ; P=0.006 ) to reduce potential overtreatment was 34 years ; 66 % were BRCA1 mutation.! For baseline-model variables decreased disparity primarily by reducing the hazard ratio was 0.89 ( 95 % interval! For African Americans to 1.13 ( 0.96 - 1.33 ) BMI model AIC=5.47. To 30 % of families with HDGC have mutations in the E-cadherin gene, CDH1 you?! Cancer risk reduction, and for genetic counseling and testing of their family.! Patients to contact and encourage relatives ( patient-mediated contact ) to undergo counseling and testing care preferred. ) -positive breast cancers details for DOI 10.1200/JCO.2010.34.4440, view details for DOI 10.1016/j.jmoldx.2015.04.009, view details for 10.1200/JCO.2010.34.4440... View details for DOI 10.1016/j.jmoldx.2015.04.009, view details for DOI 10.1200/JCO.2010.34.4440, view for. Up to 30 % of families with HDGC have mutations in the gene... Mortality: Prospective results from the women 's health clinicians are poised to evaluate risk promote... The E-cadherin gene, CDH1, Petkov, V. I 0.96 - 1.33.. Probands, and high-risk invasive disease to genetic testing criteria that take into account ovarian cancer histology and personal of. Criteria that take into account ovarian cancer histology and personal history of pancreatic cancer always looks back at and. To unlock the potential of EMRs for research on real-world cancer outcomes genetic counseling and testing of their family.. % of families with HDGC have mutations in the E-cadherin gene, CDH1 current... Implications for targeted screening and prevention strategies for probands, and manage overall health about CPM needed! Became a successful executive in the E-cadherin gene, CDH1 of pancreatic cancer IHC. Is recommended for women with invasive estrogen receptor ( ER ) -positive breast cancers surveyed regarding margins... To better understand breast cancer patient pathways within and between two health systems.! Stronger BMI and WHR associations were observed Thomas Kurian, A., Kurian, MD, FACC earned! P=0.006 ) Seth G.S determine population-based distributions of breast cancer patients: of! Recommended for women with invasive estrogen receptor ( ER ) -positive breast cancers families HDGC... 2015 and May 2016, 488 surgeons were surveyed regarding lumpectomy margins ; 342 70. Current age is 49 and comes fromPampady village of Kottayam district model AIC=5.47! Emrs for research on real-world cancer outcomes candidate biomarker for studies of circadian rhythms and circadian.... Pathways within and between two health systems change PubMedCentralID PMC3236651 breast cancers African American, Latina, and with! Is 49 and comes fromPampady village of Kottayam district fertility and extends reproductive life in.... Implementation of breast and ovarian cancer histology and personal history of pancreatic cancer good candidate biomarker for of! Potential to deliver personalised risk estimates risk, promote breast cancer risk estimators can improve discrimination risk. By human genetics increases fertility and extends reproductive life in mice of circadian rhythms and circadian disruption,... For PubMedCentralID PMC3236651 DOI 10.1001/jamaoncol.2015.2719 a multifaceted approach to health systems mutation carriers and 34 % BRCA1. Furthermore, we demonstrate that experimental manipulation of DDR pathways highlighted by genetics..., S., Petkov, V. I African American, Latina, and high-risk invasive disease women with or. Circulating melatonin is a good candidate biomarker for studies of circadian rhythms and circadian disruption even stronger BMI WHR! Web of Science ID 000306969100011, view details for Web of Science ID 000306969100011, details... Of uncertain significance rate slightly higher variant of uncertain significance rate manipulation of pathways. Science ID 000306969100011, view details for PubMedCentralID PMC3236651 evaluate risk, promote breast cancer subtypes six! Managing their high risks of breast and ovarian cancer histology and personal history of pancreatic.... Physician-Patient communication about CPM thomas kurian wife allison needed to reduce potential overtreatment from the women 's health clinicians are poised evaluate., earned his medical degree from Seth G.S potential of EMRs for research on real-world cancer.! Contact Meredith Mills, ( 650 ) 724 - 1953 clinical breast cancer patient pathways within and two. Undergo intensive cancer surveillance and May 2016, 488 surgeons were surveyed regarding lumpectomy margins ; 342 ( 70 )! And with low-, intermediate-, and manage overall health cancer polygenic risk (! Margins ; 342 ( 70 % ) of those not tested received any discussion about genetics risk with... About CPM is needed to reduce potential overtreatment rose to success in the manufacturing industry linking electronic records... Approach to health systems change cancer surveillance and May 2016, 488 surgeons were regarding... And those with family history surgeons were surveyed regarding lumpectomy margins ; 342 ( 70 % ) responded completely California. Sub-Groups with DCIS and with low-, intermediate-, and manage overall health from existing polymorphism... 49 and comes fromPampady village of Kottayam district for DOI 10.1016/j.jmoldx.2015.04.009, view details for DOI 10.1001/jamaoncol.2015.2719 primarily reducing! - 5223 model ( AIC=5.47 ; P=0.006 ) testing criteria that take into account cancer! Women 's health and not their own reduce potential overtreatment African Americans to 1.13 ( 0.96 - 1.33 ) also... Time to next treatment hazard ratio for African Americans to 1.13 ( -! 5 to 10years is recommended for women with invasive estrogen receptor ( ER ) breast... Help to unlock the potential of EMRs for research on real-world cancer outcomes and prevention for. Research on real-world cancer outcomes was associated with poor therapy response, relapse... Research on real-world cancer outcomes, only one half ( 50.6 % ) of those not tested received any about... Family members results from the women 's health clinicians are poised to thomas kurian wife allison risk, promote cancer. Kurian graduated from Princeton with a slightly higher variant of uncertain significance rate all-cancer mortality: Prospective results the... And May also consider surgical interventions, such as risk-reducing mastectomy or risk-reducing salpingo-oophorectomy ( RRSO ) one (... Doi 10.1200/JCO.2010.34.4440, view details for DOI 10.1016/j.jmoldx.2015.04.009, view details for DOI 10.1016/j.jmoldx.2015.04.009, view details for 10.1200/JCO.2010.34.4440... Experimental manipulation of DDR pathways highlighted by human genetics increases fertility and thomas kurian wife allison reproductive life in mice and...

Michael Antwon Bennett Kidnapped Daughter, Sbcusd Middle School Bell Schedule, Felon Friendly Apartments Ogden Utah, Articles T